REducing With MetfOrmin Vascular Adverse Lesions in Type 1 Diabetes (REMOVAL)

This study is currently recruiting participants.
Verified April 2013 by University of Glasgow
Sponsor:
Collaborators:
NHS Greater Glasgow and Clyde
Juvenile Diabetes Research Foundation
Imperial College London
University of Wisconsin School of Medicine and Public Health
University of Dundee
Merck Serono S.A., Geneva
Itamar-Medical, Israel
University of Western Ontario, Canada
University of Melbourne
Steno Diabetes Center
Maastricht University Medical Center
Information provided by (Responsible Party):
Prof John Petrie, University of Glasgow
ClinicalTrials.gov Identifier:
NCT01483560
First received: November 23, 2011
Last updated: April 1, 2013
Last verified: April 2013
  Purpose

The trial is conducted in the UK, Australia, Canada, Denmark and the Netherlands. The aim is to test whether 3 years treatment with metformin added to titrated insulin therapy (towards target HbA1c7.0%/53 mmol/mol) reduces atherosclerosis, as measured by progression of carotid IMT, in adults with confirmed type 1 diabetes aged 40 years and over at increased risk for cardiovascular disease.


Condition Intervention Phase
Diabetes Mellitus, Type 1
Drug: Metformin
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: Phase 3 Study of Metformin in Adults With Type 1 Diabetes

Resource links provided by NLM:


Further study details as provided by University of Glasgow:

Primary Outcome Measures:
  • Change in averaged mean far wall common carotid artery IMT [ Time Frame: 0, 12 months, 24 months, 36 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change in HbA1c [ Time Frame: Baseline, Year 1, Year 2, Year 3 ] [ Designated as safety issue: No ]
  • Change in LDL Cholesterol [ Time Frame: Baseline, Year 1, Year 2, Year 3 ] [ Designated as safety issue: No ]
  • Change in albuminuria & estimated glomerular filtration rate [ Time Frame: Baseline, Year 1, Year 2, Year 3 ] [ Designated as safety issue: No ]
    Number of participants developing new microalbuminuria; change in absolute concentration

  • Change in retinopathy stage [ Time Frame: Baseline, Year 3 ] [ Designated as safety issue: No ]
    ETDRS grade

  • Change in weight [ Time Frame: Baseline, Year 1, Year 2, Year 3 ] [ Designated as safety issue: No ]
  • Change in insulin dose [ Time Frame: Baseline, Year 1, Year 2, Year 3 ] [ Designated as safety issue: No ]
  • Change in endothelial function [ Time Frame: Baseline, Year 1, Year 3 ] [ Designated as safety issue: No ]
    RHI units


Estimated Enrollment: 500
Study Start Date: December 2011
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: October 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Metformin
Oral Metformin (as Glucophage 500mg x 2 bd) titrated from initial 500mg to target 2000mg daily
Drug: Metformin
3 years treatment duration
Other Name: Glucophage
Placebo Comparator: Placebo Drug: Placebo
3 years duration

  Eligibility

Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Type 1 Diabetes for five years or more*
  • Age 40 years or above
  • 7.0 =< HbA1c <10.0% (53 - 86 mmol/mol)

AND 3 or more of the following ten CVD risk factors:

  • BMI >27 kg/m^2
  • Current HbA1c >8.0% (64 mmol/mol)
  • Known CVD/peripheral vascular disease
  • Current smoker
  • Estimated glomerular filtration rate <90 ml/min per 1.73 m^3
  • Confirmed micro- or macroalbuminuria [according to local assays and reference ranges]
  • Hypertension (BP >=140/90mmHg or established on antihypertensive treatment)
  • Dyslipidaemia [total cholesterol >=5.0 mmol/L (200 mg/dL);OR HDL cholesterol <1.20 mmol/L (46mg/dL) [MEN]; OR <1.30 mmol/L (50 mg/dL) [WOMEN]; or triglycerides >=1.7 mmol/L (150mg/dL); or established on lipid-lowering treatment)]
  • Strong family history of CVD (at least one parent, biological aunt/ uncle, or sibling with myocardial infarction or stroke aged <60 years)
  • Duration of diabetes > 20 years

Exclusion Criteria:

  • eGFR < 45 ml/min/1.73m2
  • woman of childbearing age not on effective contraception
  • Pregnancy and/or lactation
  • Acute coronary syndrome or Stroke/Transient Ischaemic Attack within the last three months
  • NYHA stage 3 or 4 heart failure
  • Significant hypoglycaemia unawareness
  • Impaired cognitive function/ unable to give informed consent
  • Previous carotid surgery/ inability to capture adequate carotid images
  • Estimated glomerular filtration < 45ml/min/1.73m^2 (MDRD)
  • Gastroparesis
  • History of lactic acidosis
  • Other contraindications to metformin (hepatic impairment, known hypersensitivity to metformin, acute illness such as dehydration, severe infection, shock, acute cardiac failure or suspected tissue hypoxia)
  • Any coexistent life threatening condition including prior diagnosis of cancer within two years
  • History of alcohol problem or drug abuse
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01483560

Contacts
Contact: John Petrie 00 44 141 330 3325 john.petrie@glasgow.ac.uk

Locations
Australia
St Vincent's Hospital Recruiting
Melbourne, Australia
Contact: Alicia Jenkins         jenkinsa@medstv.unimelb.edu.au    
Principal Investigator: Alicia Jenkins            
Sub-Investigator: David O'Neal            
Royal Melbourne Hospital Recruiting
Melbourne, Australia
Contact: Peter Colman         peter.colman@mh.org.au    
Principal Investigator: Peter Colman            
Royal Prince Albert Hospital Recruiting
Sydney, Australia
Contact: Stephen Twigg         stwigg@med.usyd.edu.au    
Principal Investigator: Stephen Twigg            
Canada
St Joseph's Health Care Recruiting
Ontario, Canada
Contact: Irene Hramiak         irene.hramiak@sjhc.london.on.ca    
Principal Investigator: Irene Hramiak            
Ottawa Hospital Riverside Campus Not yet recruiting
Ottawa, Canada
Contact: TC Ooi         tcooi@toh.on.ca    
Principal Investigator: TC Ooi            
Denmark
Steno Diabetes Centre Not yet recruiting
Gentofte, Denmark
Contact: Peter Rossing         ltar@steno.dk    
Principal Investigator: Peter Rossing            
Netherlands
Maastricht University Medical Centre Recruiting
Maastricht, Netherlands
Contact: Coen Stehouwer         cda.stehouwer@mumc.nl    
Principal Investigator: Coen Stehouwer            
Sub-Investigator: Martijn Brouwers            
United Kingdom
Aberdeen Royal Infirmary Not yet recruiting
Aberdeen, United Kingdom
Contact: Donald Pearson         donald.pearson@nhs.net    
Principal Investigator: Donald Pearson            
Diabetes Support Unit, Ninewells Hospital and Medical School Recruiting
Dundee, United Kingdom
Contact: Graham Leese         graham.leese@nhs.net    
Principal Investigator: Graham Leese            
University Hospital North Durham Recruiting
Durham, United Kingdom
Contact: Kamal Abouglilia         kamal.abouglila@cddft.nhs.uk    
Principal Investigator: Kamal Abouglilia            
Edinburgh Western Infirmary Not yet recruiting
Edinburgh, United Kingdom
Contact: John McKnight         john.mcknight@nhs.net    
Principal Investigator: John McKnight            
Edinburgh Royal Infirmary Not yet recruiting
Edinburgh, United Kingdom
Contact: Alan Jaap         alan.jaap@nhslothian.scot.nhs.uk    
Principal Investigator: Alan Jaap            
Peninsula NIHR Clinical Research Facility, Royal Devon and Exeter NHS Foundation Trust Recruiting
Exeter, United Kingdom
Contact: Roderick Warren         roderick.warren@nhs.net    
Principal Investigator: Roderick Warren            
Sub-Investigator: Angela Shore            
Stobhill Hospital, Diabetes Clinic Recruiting
Glasgow, United Kingdom
Contact: John Petrie     0044 141 330 3325     john.petrie@glasgow.ac.uk    
Principal Investigator: Gerard McKay            
Michael White Diabetes Centre, Hull Royal Infirmary Recruiting
Hull, United Kingdom
Contact: Steve Atkin         stephen.atkin@hyms.ac.uk    
Principal Investigator: Steve Atkin            
Clinical Sciences Centre, University Hospital Not yet recruiting
Liverpool, United Kingdom
Contact: John Wilding         j.p.h.wilding@liverpool.ac.uk    
Principal Investigator: John Wilding            
Clinical Investigation Unit, International Centre for Circulatory Health, Imperial College Healthcare NHS Trust Recruiting
London, United Kingdom
Contact: Nick Oliver         nick.oliver@imperial.ac.uk    
Principal Investigator: Nick Oliver            
Wellcome Trust Clinical Research Facility, Manchester Royal Infirmary Recruiting
Manchester, United Kingdom
Contact: Rob Davies         rob.davies@cmft.nhs.uk    
Principal Investigator: Martin Gibson            
Newcastle NIHR Clinical Research Facility, Royal Victoria Hospital Recruiting
Newcastle, United Kingdom
Contact: Mark Walker         mark.walker@newcastle.ac.uk    
Principal Investigator: Mark Walker            
Diabetes Clinical Research Centre, Plymouth Recruiting
Plymouth, United Kingdom
Contact: Ann Millward         ann.millward@pms.ac.uk    
Principal Investigator: Ann Millward            
Sub-Investigator: Mike Eaton            
Salford Royal NHS Foundation Trust Recruiting
Salford, United Kingdom
Contact: Martin Gibson         martin.gibson@manchester.ac.uk    
Principal Investigator: Martin Gibson            
Sponsors and Collaborators
University of Glasgow
NHS Greater Glasgow and Clyde
Juvenile Diabetes Research Foundation
Imperial College London
University of Wisconsin School of Medicine and Public Health
University of Dundee
Merck Serono S.A., Geneva
Itamar-Medical, Israel
University of Western Ontario, Canada
University of Melbourne
Steno Diabetes Center
Maastricht University Medical Center
Investigators
Principal Investigator: John Petrie, Prof University of Glasgow
Study Director: Helen Colhoun, Prof University of Dundee
  More Information

No publications provided

Responsible Party: Prof John Petrie, Clinical Professor in Diabetic Medicine, University of Glasgow
ClinicalTrials.gov Identifier: NCT01483560     History of Changes
Other Study ID Numbers: GN10DI406, 2011-000300-18
Study First Received: November 23, 2011
Last Updated: April 1, 2013
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
United Kingdom: National Health Service
Canada: Canadian Institutes of Health Research
Australia: National Health and Medical Research Council
Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
Denmark: Danish Medicines Agency

Keywords provided by University of Glasgow:
REMOVAL
metformin
carotid IMT
LDL Cholesterol
endothelial function
retinopathy
HbA1c

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Metformin
Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 19, 2013